Pharmacopoeial Standard Guidelines

1. Regulatory Framework

The Pharmacopoeial Standards for Ayurvedic Drugs are governed under:

• Drugs and Cosmetics Act, 1940
• Drugs and Cosmetics Rules, 1945 (Rule 160–170 & Schedule T)
• Formulated and published by the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), an autonomous body under the Ministry of AYUSH.
• These standards are legally binding for all manufacturers of Ayurveda, Siddha, Unani, and Homoeopathy (ASU&H) drugs in India.

2. Objective of Pharmacopoeial Standards

The purpose of these guidelines is to:

• Ensure identity, purity, quality, and strength of Ayurvedic medicines.
• Guarantee safety for human consumption.
• Provide uniformity in dosage forms and preparation methods.
• Promote international acceptability of Indian traditional medicines.

3. Key Documents Published by Ministry of AYUSH / PCIM&H

1. Ayurvedic Pharmacopoeia of India (API) – Defines standards for raw materials and formulations.
   • Part I: Single Drugs (herbal, mineral, metal origin)
   • Part II: Compound Formulations
2. Ayurvedic Formulary of India (AFI) – Lists standardized classical formulations.
3. General Guidelines for Drug Development of Ayurvedic Formulations – Issued by CCRAS for safety, efficacy, and clinical evaluation.
4. GMP Guidelines (Schedule T) – Good Manufacturing Practices specific to Ayurvedic manufacturing units.

4. Parameters for Ensuring Purity, Safety, and Dosage

A. Identification & Authentication

• Botanical and scientific names must match official monographs in the Ayurvedic Pharmacopoeia of India.
• Raw materials are verified through:
  • Macroscopic & Microscopic examination
  • Chromatographic profiling (TLC/HPTLC)
  • Chemical fingerprinting

B. Purity Standards

Each monograph specifies limits for:

1. Foreign matter: ≤2%
2. Moisture content: ≤12%
3. Total ash: ≤5–10% depending on plant type
4. Acid-insoluble ash: ≤1–2%
5. Alcohol and water-soluble extractive values: Defined range
6. Heavy metals:
   • Lead (Pb) ≤10 ppm
   • Arsenic (As) ≤3 ppm
   • Cadmium (Cd) ≤0.3 ppm
   • Mercury (Hg) ≤1 ppm
7. Pesticide residues: Within WHO/FAO permissible limits
8. Aflatoxin limits:
   • Total aflatoxins ≤30 ppb
   • Aflatoxin B₁ ≤10 ppb
9. Microbial load:
   • Total bacterial count ≤10⁵ CFU/g
   • Total fungal count ≤10³ CFU/g
   • E. coli, Salmonella, Staphylococcus aureus – absent

C. Safety Evaluation

• Toxicity Studies: Acute, sub-acute, and chronic toxicity tests must be performed for new or proprietary Ayurvedic formulations (CCRAS guideline).
• Metallic/Mineral Preparations (Bhasma):
  • Must undergo Shodhana (purification) and Marana (incineration) as per classical texts.
  • Must be tested for particle size, bioavailability, and absence of free toxic metals.
• Clinical Safety: Required for non-classical or modified formulations.

D. Strength and Potency

• Defined through marker compound assays and physico-chemical constants (like extractive values, pH, viscosity).
• Shelf-life and potency determined by stability testing (as per Rule 161B of the Drugs & Cosmetics Rules).

E. Dosage Standards

• Dosage forms include Churna, Avaleha, Vati, Taila, Asava-Arishta, Bhasma, etc.
• Dosages are standardized in Ayurvedic Formulary of India (AFI) — based on:
  • Age, body weight, dosha condition, and disease state.
  • Example:
    • Churna (powder): 3–5 g twice daily
    • Kwatha (decoction): 50–100 ml twice daily
    • Vati (tablet): 1–2 tablets twice daily
    • Asava/Arishta: 10–20 ml twice daily after meals

5. Good Manufacturing Practices (GMP – Schedule T)

To maintain consistency and safety:

• Use authentic raw materials verified with pharmacopoeial standards.
• Maintain hygienic processing, calibrated equipment, and trained staff.
• Conduct in-process quality checks and batch record documentation.
• Maintain stability data, labeling accuracy, and storage conditions.

6. Laboratory Testing and Certification

Testing must be done at:

• State Drug Testing Laboratories (ASU&H) or
• Approved private labs recognized by PCIM&H.

Each drug is tested for:

• Identity
• Purity
• Strength
• Safety parameters

7. Institutional Framework Under Ministry of AYUSH

• Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), Ghaziabad – Formulation and publication of pharmacopoeial standards.
• Central Council for Research in Ayurvedic Sciences (CCRAS) – Research and safety validation.
• National Institute of Ayurveda (NIA), Jaipur – Academic and technical input.
• IMPCL (Indian Medicines Pharmaceutical Corporation Ltd.) – Produces pharmacopoeial-grade medicines.

8. Legal Enforcement

• Only Ayurvedic drugs conforming to Pharmacopoeial Standards can be licensed and marketed in India.
• Non-compliance can lead to classification as “Misbranded” or “Spurious” under Sections 33E–33EE of the Drugs & Cosmetics Act.

9. Summary Table

Reference Links (Official)

• Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H)
• Ayurvedic Pharmacopoeia of India (API)
• Ministry of AYUSH – Drugs & Cosmetics Act & Rules
• CCRAS – General Guidelines for Drug Development of Ayurvedic Formulations